

Howard A. Zucker, M.D., J.D. Acting Commissioner of Health

Sue Kelly Executive Deputy Commissioner

Medicaid Fee- for- Service Providers Dispense Brand Name Drug when Less Expensive than Generic Program

Effective October 7, 2014, the following changes will be made to the Dispense Brand Name Drug when Less Expensive than Generic Program:

• Evista, Lovenox, Prevpac and Prograf will be removed from the Program.

In conformance with State Education Law which intends that patients receive the lower cost alternative, brand name drugs included in this program:

- Do not require 'Dispense as Written' (DAW) or 'Brand Medically Necessary' on the prescription.
- Have a generic copayment.
 - Are paid at the Brand Name Drug reimbursement rate or usual and customary price, whichever
- is lower (SMAC/FUL are not applied).
 Do not require a new prescription if the drug is removed from this program.

IMPORTANT BILLING INFORMATION

Prescription claims submitted to the Medicaid program **do not require** the submission of Dispense as Written/Product Selection Code of '1'; **Pharmacies can submit any valid NCPDP field (408-D8) value.**

List of Brand Name Drugs included in this program* (Updated 9/23/14):

Accolate	Epivir HBV tablet	Solaraze
Adderall XR	Felbatol	Soriatane
Alphagan P 0.15%	Focalin XR(15mg,30mg,40mg)	Symbyax
Aldara	Gabitril 2mg, 4mg	Tegretol suspension
Astepro	Hepsera	ТОВІ
Bactroban cream	Kadian	Tobradex drops
Carbatrol	Lidoderm	Toprol XL
Catapres-TTS	Mepron	Trileptal suspension
Combivir	Myfortic	Trizivir
Depakote sprinkle	Niaspan	Wellbutrin
Diastat	Ortho Evra	Wellbutrin XL
Diovan HCT	Pulmicort Respules	

^{*}List is subject to change

Please keep in mind that drugs in this program may be subject to prior authorization requirements of other pharmacy programs, promoting the use of the most cost-effective product.

